EXHIBITOR

ISU ABXIS is pioneering the discovery of engineered antibody-based immunotherapy to target tumors and rare diseases. Founded in 2001 to develop innovative antibody-based therapeutics to treat cancer and rare disease, the name ABXIS reflects our dedication to becoming an axis of antibody (Ab) therapeutics. By providing new ways of combatting cancer and rare diseases, ISU ABXIS will fulfill its vision of enhancing lives and easing the suffering of patients worldwide. ISU Abxis is currently improving patient’s life with LSD disease with Fabgal® (Agalsidase beta), a treatment for Fabry disease, and Abcertin® (Imiglucerase), a treatment for Gaucher’s disease.